Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: A.D.A.M. Innovations, Celltrion, Genedx, Rhythio Medical, Sophia Genetics, Wellscare.
Chugai Pharmaceutical Co. Ltd. and Rani Therapeutics LLC have entered into a collaboration and global license agreement to develop and commercialize an oral product that encompasses Rani’s oral delivery technology, the Ranipill, and Chugai’s rare disease antibody in development.
Grail LLC has presented data showing that when added to standard screening procedures for breast, cervical, colorectal and lung cancers, its Galleri circulating tumor DNA test led to a sevenfold increase in the number of cancers detected.
Boston Scientific Corp. moved to acquire the balance of Nalu Medical Inc. in a $533 million cash deal, expanding its chronic pain portfolio with the addition of peripheral nerve stimulation. The Nalu neurostimulation system delivers mild electrical impulses to interrupt aberrant pain signals from nerves in the shoulder, knee and lower back before they reach the brain.
Total arterial revascularization (TAR) might not be the most popular approach to coronary artery bypass grafting (CABG), but it is gaining in popularity according to a new study appearing in the Journal of the American College of Cardiology. The authors said that TAR provides superior mortality outcomes compared to bypass grafting that relies on both veins and arteries for graft materials, a finding that might suggest lower rates of downstream angioplasty and stenting.
Med-tech M&A activity totaled $4.84 billion in September, down slightly from $7.29 billion in July but stronger than August’s $2.42 billion. Year-to-date disclosed deal value reached $37.21 billion, roughly on par with the $41.79 billion recorded during the same period in 2024. While still far below the highs of 2021 and 2022, when annual totals surpassed $100 billion, the 2025 data show that consolidation within the med-tech sector remains steady.
RSS
